Clinical Scorecard: Scrambler Therapy with Duloxetine-Based Usual Care vs. Duloxetine-Based Usual Care for Chemotherapy-Induced Peripheral Neuropathy

At a Glance

Key Highlights

• Primary objective: Assess superiority of Scrambler therapy with duloxetine over duloxetine-based usual care.
• Inclusion criteria: Average pain score of at least 4/10 and CTCAE grade 2 neuropathies.
• Exclusion criteria include severe skin conditions, certain psychiatric disorders, and current use of MAOIs.

Guideline-Based Recommendations

Diagnosis

• CIPN diagnosed based on chart review or oncologist diagnosis.

Management

• Scrambler therapy combined with duloxetine for pain management.

Monitoring & Follow-up

• Pain assessed using BPI-Short Form and EORTC CIPN-20.

Risks

• Exclusion of patients with severe depression, uncontrolled epilepsy, and other specified conditions.

Patient & Prescribing Data

Adults with cancer experiencing CIPN.

Focus on achieving at least a 50% reduction in pain scores.

Clinical Best Practices

• Ensure proper patient selection based on inclusion and exclusion criteria.
• Monitor pain and function regularly during treatment.

Related Resources & Content

• ClinicalTrials.gov